Drug Type siRNA |
Synonyms LY-3819469 |
Target |
Action inhibitors |
Mechanism lipoprotein(a) inhibitors, RNA interference |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Phase 3 | United States | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | China | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Japan | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Argentina | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Australia | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Austria | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Belgium | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Brazil | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Canada | 05 Mar 2024 | |
Atherosclerosis | Phase 3 | Czechia | 05 Mar 2024 |
Phase 2 | 320 | (16 mg LY3819469) | snlnnrvhbz(wbdxobrywv) = krwgxotchq xturpguldv (ksabdbtwah, 7.37) View more | - | 28 May 2025 | ||
(96 mg LY3819469) | snlnnrvhbz(wbdxobrywv) = ckkqvyrnfo xturpguldv (ksabdbtwah, 2.16) View more | ||||||
Phase 2 | 320 | lepodisiran 16 mg (at baseline and again at day 180) | bfidrlogrz(hxeaktahka) = Dose-dependent, generally mild injection-site reactions occurred in up to 12% (8 of 69) of the participants in the highest lepodisiran dose group. wptxdtnann (kspelwqafw ) | Positive | 30 Mar 2025 | ||
lepodisiran 96 mg (at baseline and again at day 180) | |||||||
Phase 1 | lipoprotein(a) serum concentrations | 48 | ggjokhhgsd(keegpwcgcw) = 1 serious adverse event occurred ecmlwuxjiz (xuaozjmzca ) | Positive | 05 Dec 2023 | ||